Chromosomal translocations that generate in-frame oncogenic gene fusions are notable examples of the success of targeted cancer therapies 1-3 . We have previously described gene fusions of FGFR3-TACC3 (F3-T3) in 3% of human glioblastoma cases 4 . Subsequent studies have reported similar frequencies of F3-T3 in many other cancers, indicating that F3-T3 is a commonly occuring fusion across all tumour types 5,6 . F3-T3 fusions are potent oncogenes that confer sensitivity to FGFR inhibitors, but the downstream oncogenic signalling pathways remain unknown 2,4-6 . Here we show that human tumours with F3-T3 fusions cluster within transcriptional subgroups that are characterized by the activation of mitochondrial functions. F3-T3 activates oxidative phosphorylation and mitochondrial biogenesis and induces sensitivity to inhibitors of oxidative metabolism. Phosphorylation of the phosphopeptide PIN4 is an intermediate step in the signalling pathway of the activation of mitochondrial metabolism. The F3-T3-PIN4 axis triggers the biogenesis of peroxisomes and the synthesis of new proteins. The anabolic response converges on the PGC1α coactivator through the production of intracellular reactive oxygen species, which enables mitochondrial respiration and tumour growth. These data illustrate the oncogenic circuit engaged by F3-T3 and show that F3-T3positive tumours rely on mitochondrial respiration, highlighting this pathway as a therapeutic opportunity for the treatment of tumours with F3-T3 fusions. We also provide insights into the genetic alterations that initiate the chain of metabolic responses that drive mitochondrial metabolism in cancer.
Data Fig. 1c and Supplementary Table 1 ). We confirmed the expression changes of mitochondrial genes by quantitative PCR with reverse transcription (RT-qPCR) (Extended Data Fig. 1d ).
Compared to human astrocytes expressing the empty vector or F3-T3(K508M), F3-T3 human astrocytes exhibited increased levels of mitochondrial DNA, mitochondrial mass (MitoTracker Red) and produced higher levels of ATP (Fig. 1c, d and Extended Data Fig. 1e ). F3-T3 increased respiratory complex proteins (SDHB, UQCRC1 and ATP5A1) and the mitochondrial membrane transporter VDAC1 (Extended Data Fig. 1f ). We also found higher levels of VDAC1 and NDUFS4 in tumours generated from mouse glioma stem cells (mGSCs) expressing human F3-T3 and small hairpin RNA (shRNA) against Trp53 (shTrp53) (hereafter F3-T3;shTrp53) than in tumours formed by mGSCs expressing oncogenic HRAS(12V) and shTrp53 (hereafter HRAS(12V);shTrp53) 4, 7 (Extended Data Fig. 1g ). Introduction of F3-T3 in human astrocytes, RPE and U251 cells increased the basal and maximal oxygen consumption rate (OCR) of these cells compared to cells transduced with F3-T3(K508M) or empty vector and this effect was reversed by FGFR-TK inhibition with AZD4547 in cells expressing exogenous F3-T3 and human glioblastoma (GBM)-derived GSC1123 cells with endogenous F3-T3 4 (Fig. 1e and Extended Data Fig. 2a-d ). F3-T3 elicited only a mild increase in the extracellular acidification rate (ECAR), leading to an increase in the OCR:ECAR ratio (Extended Data Fig. 2e , f). After treatment with the inhibitor of ATP synthase oligomycin, F3-T3 human astrocytes displayed reduced ATP levels and cell growth (by more than 70%) but were resistant to the substitution of glucose with galactose in the culture medium, a condition that imposes oxidative metabolism and markedly affected cell growth of human astrocytes treated with vector (Extended Data Fig. 2g, h) . A 72-h treatment with the mitochondrial inhibitors metformin, menadione or tigecycline impaired growth of GSC1123 cells but was ineffective in GSC308 F3-T3-negative gliomaspheres 4 (Fig. 1f) . Similarly, mitochondrial inhibitors reduced the viability of F3-T3;shTrp53 mGSCs but did not affect HRAS(12V);shTrp53 mGSCs ( Fig. 1g and Extended Data Fig. 2i-k) . However, tigecycline decreased COX1 and COX2, two respiratory complex subunits translated by mitochondrial ribosomes 8 , and mitochondrial inhibitors reduced ATP production, indicating that these compounds were similarly active in both cell types (Extended Data Fig. 2l, m) . We also found that treatment with tigecycline (50 mg kg −1 ) suppressed tumour growth of F3-T3;shTrp53 mGSCs glioma xenografts with a more than 50% reduction in tumour volume after six days, the last day on which all controls were alive. At the end of the experiment (day 11), three of the eight mice in the control group had been euthanized, whereas all mice receiving tigecycline were alive (n = 10; Fig. 1h and Extended Data Fig. 2n ).
To identify F3-T3 substrates that drive oxidative metabolism, we performed anti-phosphorylated tyrosine (phospho-tyrosine) immunoprecipitation of tryptic digests of total cellular proteins from human astrocytes expressing F3-T3, F3-T3(K508M) or the empty vector, followed by identification of phosphopeptides by liquid chromatographytandem mass spectrometry (Supplementary Table 2 ). As expected, F3-T3 showed the largest changes in phospho-tyrosine; Y647 in FGFR3 and Y684 in TACC3 showed the highest and second highest enrichment in phosphorylation, respectively. After the enrichment seen in F3-T3, the next most enriched phospho-tyrosine was Y122 of PIN4 (hereafter PIN4(Y122)), a poorly studied homologue of the cancer-driver PIN1 peptidyl-prolyl-trans-isomerase [9] [10] [11] (Supplementary Table 2 ). This residue (Y122) is conserved in PIN4 across evolution and we found that F3-T3 interacts with endogenous PIN4 (Extended Data Fig. 3a, b ). Analysis of anti-phosphotyrosine immunoprecipitations revealed that only cells expressing active F3-T3 contained tyrosine-phosphorylated PIN4, PKM2, DLG3, C1orf50 and GOLGIN84, whereas tyrosinephosphorylated HGS was also present in FGFR3-expressing cells ( Fig. 2a and Extended Data Fig. 3c, d) . Treatment of GSC1123 cells with AZD4547 removed constitutive tyrosine phosphorylation of F3-T3, PIN4, PKM2, GOLGIN84 and C1orf50, whereas phospho-ERK, phospho-Stat3 and phospho-AKT were not changed (Extended Data Fig. 3e, f) . We confirmed F3-T3-specific tyrosine phosphorylation of exogenous wild-type PIN4, PKM2, GOLGIN84, DLG3 and C1orf50, but phosphorylation of the corresponding un-phosphorylatable tyrosine to alanine or phenylalanine phospho-mutants was greatly reduced (Extended Data Fig. 3g ). We generated and validated a phosphorylation-specific antibody against phosphorylated PIN4(Y122) (phospho-PIN4(Y122)). The antibody detected PIN4 in cells expressing F3-T3, but not in cells transduced with vector, FGFR3 or F3-T3(K508M) (Extended Data Fig. 3h , i). Phospho-PIN4(Y122) was readily detected in F3-T3;shTrp53 mGSCs and xenografts but was absent in HRAS(12V);shTrp53 mGSCs and corresponding tumours (Extended Data Fig. 4a, b ). Immunostaining of phospho-PIN4(Y122) in primary human GBM revealed that tumours with F3-T3 (n = 14) expressed much higher levels of phospho-PIN4(Y122) than tumours lacking F3-T3 fusions (n = 35, 15 of which expressed EGFR-SEPT14, a different receptor tyrosine kinase gene fusion that signals through phospho-STAT3 12 ; Fig. 2b and Extended Data Fig. 4c ).
Next, we expressed wild-type and the corresponding phosphotyrosine mutants of PIN4, PKM2, DLG3, C1orf50 and GOLGIN84 in F3-T3 human astrocytes and measured oxidative metabolism. Expression of wild-type and tyrosine to alanine or phenylalanine mutants of PKM2, DLG3, C1orf50 and GOLGIN84 failed to affect the increased OCR profile of F3-T3 human astrocytes (Extended Data Fig. 4d-g) . Conversely, PIN4(Y122F) but not wild-type PIN4 (PIN4(WT)) reverted basal and maximum OCR levels of F3-T3 human astrocytes to the levels of vector-expressing human astrocytes ( Fig. 2c and Extended Data Fig. 4h ). We observed similar effects in F3-T3 human astrocytes in which endogenous PIN4 had been silenced and replaced by the un-phosphorylatable PIN4(Y122F) phospho-mutant ( Fig. 2d and Extended Data Fig. 4i ). Expression of PIN4(Y122F) and PIN4(Y122A) phospho-mutants reversed the F3-T3-mediated increase in ATP (Extended Data Fig. 4j ). Expression of PIN4(Y122F) also impaired soft agar clonogenicity ( Fig. 2e) .
To identify the gene expression signature associated with F3-T3 in human tumours, we benchmarked different statistical methods for the analysis of imbalanced datasets using synthetic data and the Vehicle Tigecycline (50 mg kg -1 ) (c) or mean ± s.d. (d-g) of n = 3 technical replicates (e-g) or n = 6 (c) and n = 12 replicates (d) from two independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, two-tailed t-test with unequal variance.
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GBM transcriptome from The Cancer Genome Atlas (TCGA) 13 . The combination of the easy ensemble (ee) undersampling technique and Mann-Whitney-Wilcoxon (MWW) test statistics (ee-MWW) exhibited the best performance for correct identification of imbalanced samples and reproducible clustering (Supplementary Information  and Supplementary Table 3 ). We used ee-MWW to generate a ranked list of genes discriminating F3-T3-positive samples in the GBM dataset of the TCGA and built a hierarchical cluster (confirmed by consensus clustering), including a small cluster of nine F3-T3-positive samples and nine fusion-like GBM (Fig. 3a , Extended Data Fig. 5a and Supplementary Table 4 ). The most significant biological processes enriched in F3-T3-positive GBM were mitochondrial categories ( Fig. 3b and Extended Data Fig. 5b ). Mitochondrial functions were also increased in fusion-like GBM, which were enriched for amplification and high expression of mitochondrial RNA polymerase (POLRMT, Extended Data Fig. 5c-e ). Immunostaining of oxidative phosphorylation biomarkers in an independent GBM cohort revealed that F3-T3-positive tumours expressed higher levels of mitochondrial proteins ( Fig. 3c and Extended Data Fig. 5f ). The ee-MWW method clustered tumours with other rare oncogenes (oncogenic RAS in GBM and invasive breast carcinoma, EGFR-SEPT14 gene fusion in GBM 12 ) and identified their associated biological functions (Extended Data Fig. 5g -i and Supplementary Table 5 ). Using ee-MWW, we detected small and homogeneous clusters of F3-T3-positive tumours enriched for mitochondrial categories in each tumour containing recurrent F3-T3 fusions in the TCGA dataset (pan-glioma, lung squamous cell carcinoma, head and neck squamous cell carcinoma, oesophageal carcinoma, urothelial bladder carcinoma and cervical squamous cell carcinoma and endocervical adenocarcinoma; Extended Data Fig. 6a-k and Supplementary Table 6 ). The transcriptional similarity of F3-T3-positive glioma was confirmed by Topological Data Analysis 14, 15 (Extended Data Fig. 6l ). Finally, expression of the F3-T3 fusion gene correlated with mitochondrial activities in the analysis of multiple cancer types (Extended Data Fig. 6m ).
To identify the transcription factors that are causally related to the gene expression signature that is activated in F3-T3-positive glioma (master regulators) 16 , we assembled transcriptional networks from the GBM and pan-glioma datasets using the regularized gradient boosting machine algorithm that was developed for the inference of gene regulatory networks 17 . In both datasets, the two most active master regulators of F3-T3-positive tumours were PPARGC1A and ESRRG (encoding the PGC1α transcriptional coactivator and the nuclear receptor ERRγ, respectively; Fig. 3d , Extended Data Fig. 6n and Supplementary Table 7 ). Expression of PPARGC1A and ESRRG mRNA was higher in F3-T3-positive than F3-T3-negative GBM (Extended Data Fig. 6o ). Because PGC1α is a coactivator of the oestrogen-related receptor (ERR) subfamily of nuclear receptors and acts as a master regulator of mitochondrial biogenesis and metabolism 18, 19 , we investigated whether PGC1α and ERRγ enable the mitochondrial functions induced by F3-T3. Introduction of F3-T3 in human astrocytes expressing PIN4(WT) increased PPARGC1A mRNA and PGC1α protein and the expression of genes involved in reactive oxygen species (ROS) detoxification 20 (Extended Data Fig. 7a-d and Supplementary  Table 7 ). Accordingly, PGC1α accumulated at higher levels in F3-T3-positive GSC1123 cells and F3-T3;shTrp53 mGSCs compared to F3-T3-negative GSC308 cells and HRAS(12V);shTrp53 mGSCs, respectively ( Fig. 3e ). However, replacement of PIN4 with the un-phosphorylatable Y122F mutant PIN4(Y122F) blunted F3-T3-mediated induction of PGC1α (Extended Data Fig. 7a , c). The inhibition of mitochondrial metabolism and reduction in soft agar clonogenicity by PIN4(Y122F) in F3-T3 human astrocytes were both rescued by overexpression of PGC1α(WT). Conversely, PGC1α(L2L3A), which contains mutations in the nuclear receptor boxes L2 and L3 that are critical for binding ERRγ 18 could not rescue F3-T3-mediated activation of mitochondrial metabolism in F3-T3 human astrocytes expressing PIN4(Y122F) ( Fig. 3f and Extended Fig. 7q ) and impaired in vivo tumour growth of F3-T3;shTrp53 mGSCs but not HRAS(12V)shTrp53 mGSCs (Extended Data Fig. 7r -v). Next, we developed a brain tumour model in Drosophila by ectopically expressing human F3-T3 using the glial-specific driver repo-Gal4 (ref. 21) . repo-Gal4-F3-T3 transgenic flies manifested glial neoplasia with enlargement and malformation of the larval brain lobe and ventral nerve cord, leading to larval lethality (Extended Data Fig. 8a, b ). Cell number and proliferation of glial cells were enhanced in repo-Gal4-F3-T3 flies (Extended Data Fig. 8c, d ). Cell-autonomous RNA interference (RNAi)-mediated knockdown of spargel (srl, the Drosophila orthologue of PPARGC1A) 22 in repo-Gal4-F3-T3 flies reduced glial tumour volume and decreased the number of Repo + glial cells, without affecting repo-Gal4-driven F3-T3 protein expression in F3-T3-expressing flies or normal brain development in wild-type animals without F3-T3 (Fig. 3j , k and Extended Data Figs 8e-g, 9a-d). srl knockdown did not rescue Repo-Gal4-F3-T3 animals to adult viability, confirming that suppressors of glial neoplasia in Drosophila are infrequent rescuers of organismic lethality 23 (Extended Data Fig. 9e ). srl knockdown in a Drosophila model of glioma driven by constitutively active EGFR (dEGFR λ ) and PI3K (Dp110 CAAX ) in the glial lineage 24 resulted in minor to no effects on tumour volume, thus highlighting the specific sensitivity of F3-T3 tumorigenesis to the perturbation of srl expression (Extended Data Fig. 9f , g). RNAi-mediated knockdown of the Drosophila oestrogen-related receptor (ERR) also reduced F3-T3 glial tumour volume (Extended Data Fig. 9h , i).
To determine the mechanism by which phospho-PIN4(Y122) mediates F3-T3 signalling, we studied the subcellular compartmentalization of PIN4 and phospho-PIN4(Y122) and sought to uncover the set of cellular proteins interacting with PIN4. Unphosphorylated PIN4 was diffusely localized in the cytoplasm and nuclear membrane whereas phospho-PIN4(Y122) was concentrated in larger cytoplasmic vesicle-like structures that co-localized with F3-T3 (Extended Data Figs 3h, 10a, b). Using mass spectrometry analysis of PIN4 immunoaffinity complexes, we found that the peroxisomal biogenesis complex 25 formed by PEX1 and PEX6 is the top ranking PIN4 interactor. Other PIN4-associated proteins are implicated in vesicle formation and trafficking, nuclear and mitochondrial RNA metabolism and translation, ribosomal activity and nuclear pore/envelope functions (Extended Data Fig. 10c, d and Supplementary Table 8 ). Quantitative immunofluorescence revealed that PEX1 increased 2.7-fold in F3-T3 human astrocytes without changes in PEX1 mRNA (Fig. 4a, b and Extended Data Fig. 10e , f). To investigate whether F3-T3 signals through phospho-PIN4(Y122) to promote peroxisome biogenesis, we acutely transduced human astrocytes with a F3-T3-expressing lentivirus, and found that both phospho-PIN4(Y122) and the total number of PMP70-positive peroxi somes were increased after four days (4.3 fold increase in peroxisomes per cell; Fig. 4c, d and Extended Data Fig. 10g ). Phospho-PIN4(Y122)-positive cytoplasmic structures in F3-T3 human astrocytes, but not unphosphorylated PIN4 in vectortransduced human astrocytes, colocalized with PMP70, indicating that phospho-PIN4(Y122) trafficks to new peroxisomal membranes ( Fig. 4e ). Increased peroxisome biogenesis induced by acute expression of F3-T3 was prevented when F3-T3 was introduced in cells in which PIN4 had been replaced by the unphosphorylatable PIN4(Y122F) mutant ( Fig. 4f ). F3-T3 also induced a phospho-PIN4(Y122)-dependent early increase in new protein synthesis ( Fig. 4g and Extended Data Fig. 10h ). Conversely, PGC1α and mitochondrial gene expression were unchanged four days after acute expression of F3-T3 but increased after eight days ( Fig. 4h and Extended Data Fig. 10i ). Peroxisome biogenesis and new protein synthesis can both generate ROS, and ROS are crucial inducers of PGC1α 20, 26, 27 . F3-T3 but not F3-T3(K508M) increased ROS at the four-day time point and this effect required PIN4(Y122) phosphorylation (Fig. 4i , j and Extended Data Fig. 10j ). Treatment of F3-T3 human astrocytes with the ROS inhibitor N-acetyl-l-cysteine eliminated approximately 70% of the increase in PGC1α induced by F3-T3 ( Fig. 4k ), thus indicating that ROS are responsible for most of the increase in PGC1α induced by F3-T3.
In conclusion, we describe, using an integrated computational and experimental framework, the chain of events propagated by F3-T3 in cancer. Signalling through phospho-PIN4(Y122) triggers vesicle trafficking to deliver building blocks for biogenesis of peroxisomes and new protein synthesis. The coordinated activation of these anabolic pathways results in the accumulation of ROS, which in turn increases PGC1α-ERRγ and mitochondrial metabolism. Thus, rather than impinging exclusively on mitochondrial circuits, the oncogenic signals driving mitochondrial respiration operate within larger contexts of anabolic effectors. Dependency on mitochondrial metabolism of GBM with F3-T3 suggests that inhibitors of oxidative phosphorylation may be beneficial for patients with F3-T3-positive tumours.
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Datasets. Tumour sample data are from the TCGA. Details about the cohorts and analysed samples can be found in the Supplementary Information. Resampling methods for ranked list generation in imbalanced datasets. Preliminary testing and the ee-MWW values are reported in the Supplementary Information. Gene Ontology networks. Gene Ontology (GO) enrichment was computed using MWW test statistics for the genes positively regulated in tumours with FGFR3-TACC3 or other genetic alterations of interest (for example, RAS and EGFR-SEPT14). The significant GO terms from MWW-gene set test (GST) analysis (Supplementary Information) were further analysed using the Enrichment Map 28 application of Cytoscape 29 . In the network, nodes represent the terms and edges represent known term interactions and are defined by the number of shared genes between the pair of terms. Size of the nodes is proportional to statistical significance of the enrichment ( Fig. 1b and Extended Data Fig. 1c ) or the number of genes in the category ( Fig. 3b and Extended Data Figs 5c, 6c, f, h). The overlap between gene sets is computed according to the overlap coefficient (OC), defined as:
where A and B are two gene sets, and |X| equals to the number of elements within set X 30 . We set a cutoff of OC > 0.5 to select the overlapping gene sets. Correlation analysis between GO NES and the expression of F3-T3. We selected 19 human samples with F3-T3 fusions from ref. 31 and the TCGA fusion gene Data Portal 32 . Starting from fastq data, we applied the ChimeraScan pipeline 33 to compute the total number of reads supporting the fusion ( Supplementary Table 6m ). From TCGA, we obtained the legacy level 3 RNA sequencing by expectation maximization (RSEM) counts of the samples. By using the EDASeq methodology 34 , we corrected the counts for GC content and applied full-quantile normalization. We transformed the normalized counts in the transcripts per million abundance quantification, applied MWW-GST to each sample and collected the NES. We used the MDSigDB collections c5.bp, c5.mf, c5.cc and hallmark collections of gene sets. We compared each gene set with the number of reads supporting the F3-T3 fusions by using the Spearman's rank correlation index ( Supplementary  Table 6n ). To test the correlation, we assumed the alternative hypothesis of the correlation greater than zero.
Assembly of the transcriptional interactomes. To identify master regulators of the gene expression signature activated in the F3-T3-positive glioma subgroup, we first assembled independent transcriptional networks from gene expression profiles of GBM and pan-glioma datasets using the regularized gradient boosting machine algorithm (RGBM) 17 (package available from CRAN at https://cran.r-project.org/ web/packages/RGBM/index.html). RGBM was used to identify regulators of the molecular subtypes of brain tumours 17, 35 . We used gene expression profiles and a predefined list of 2,137 gene regulators or transcription factors (master regulators) as input. This process was independently applied to obtain GBM and pan-glioma transcriptional interactomes comprising 430,104 (median regulon size: 203) and 300,969 (median regulon size: 141) transcriptional interactions, respectively, of which 188,238 were overlapping. Master regulator activity. To identify the master regulators of the gene expression signature activated in F3-T3-positive glioma, we modified a method that we had previously described 16 . In brief, the activity of a master regulator MR, defined as the index that quantifies the activation of the transcriptional program of that specific master regulator in each sample S i , is calculated as follows:
where + t ki is the expression level of the k-th positive target of the master regulator in the i-th sample, − t ji is the expression level of the j-th negative target of the master regulator in the i-th sample, N (or M) the number of positive (or negative) targets present in the regulon of the considered master regulator. If Act(S i , MR) > 0, the master regulator is activated in that particular sample, if Act(S i , MR) < 0, the master regulator is inversely activated, if Act(S i , MR) ≈ 0, it is deactivated. We used the MWW test to select master regulators that showed a significant difference between the F3-T3-positive samples and all the other samples. In Supplementary Table 7a https://github.com/paultpearson/TDAmapper). TDA was performed using the expression matrix of the top 100 genes differentially expressed between F3-T3-positive tumours and the remaining tumours as shown in Extended Data Fig. 6a . Mapper uses a dimentionality reduction algorithm and produces a topological representation of the data that preserves locality. The projection space of the dimentional-reduction algorithm is covered with overlapping bins. The data points that fall in each bin are then clustered in the original high-dimentional space. A network is constructed by assigning a node to each cluster, and clusters that share one or more samples are connected by an edge. The result is a low-dimensional network representation of the data in which nodes represent sets of samples with similar global transcriptional profiles, and edges connect nodes that have at least one sample in common. For our analysis we used 2D Locally Linear Embedding 37 as dimentional-reduction algorithm and variance normalized Euclidean metric 38 as distance. Single-linkage clustering was performed in each of the pre-images of the bins using a previously described algorithm 39 . The number of bins (resolution) for each dimension was 20 and the degree of overlap (gain) between neighbouring bins was 66%. The size of the bin was chosen such that the number of samples in each row or column of bins was the same. The open-source implementations of Mapper produce results consistent with those obtained from the Ayasdi platform 40 . Transcriptomic analysis of human astrocytes. We performed comparative analysis of gene expression of human astrocytes transduced with a lentivirus expressing F3-T3 treated with vehicle (F3-T3 and DMSO, n = 5 replicates), F3-T3 treated with the FGFR inhibitor PD173074 for 12 h (F3-T3 and PD173074, n = 5 replicates), F3-T3(K508M) treated with vehicle (F3-T3(K508M) and DMSO, n = 3 replicates) and empty vector treated with vehicle (vector DMSO, n = 3 replicates). Expression data were obtained using the Illumina human HT12v4 gene expression array. The list of 4,034 differentially expressed genes between the F3-T3 and DMSO and F3-T3 and PD173074 groups (t-test P < 0.01 and MWW test P < 0.01) was used to construct a heat map comprising the whole dataset in which vector and DMSO and F3-T3(K508M) and DMSO are control groups. Samples were clustered using the hierarchical clustering algorithm based on the Ward linkage method and Euclidean distance as implemented in R. Finally, the GO enrichment analysis was performed using the ranked list obtained from three independent comparisons: F3-T3 versus F3-T3 treated with PD173074; F3-T3 versus F3-T3(K508M); F3-T3 versus vector using the Java version of GSEA. For each comparison, statistically significant GO terms with Q < 10 −6 were selected. The statistically significant pathways common to all three comparisons were included in the construction of the visual network using the Enrichment Map application 28 of Cytoscape 29 . The microarray data have been deposited in ArrayExpress with accession number E-MTAB-6037. Identification of proteins phosphorylated by the F3-T3 gene fusion using mass spectrometry. Cells were lysed in buffer containing 9 M urea, 20 mM HEPES pH 8.0, 0.1% SDS and a cocktail of phosphatase inhibitors. Six milligrams of protein were reduced with 4.5 mM DTT, alkylated with 10 mM iodoacetamide and digested with trypsin overnight at 37 °C. Samples were desalted on a C18 cartridge (Sep-Pak plus C18 cartridge, Waters). Each sample was prepared in triplicate. Phosphopeptide enrichments were performed as previously described 41 . An LTQ Orbitrap XL (ThermoFisher) in-line with a Paradigm MS2 HPLC (Michrom bioresources) was used to acquire high-resolution mass spectrometry and tandem mass spectrometry data. Technical duplicate data for each of the metal-oxide affinity chromatography elutions and triplicate data for the phosphotyrosine immunoprecipitation samples were acquired.
RAW files were converted to mzXML using msconvert 42 and searched against the Swissprot Human protein database (9 January 2013 release) appended with common proteomics contaminants and reverse sequences as decoys. Searches were performed with X!Tandem (version 2010.10.01.1) using the k-score plugin 43, 44 . For all searches the following search parameters were used: parent monoisotopic mass error of 50 parts per million (p.p.m.); fragment ion error of 0.8 daltons; allowing for up to two missed tryptic cleavages. Variable modifications were oxidation of methionine (+15.9949@M), carbamidomethylation of cysteine (+57.0214@C), and phosphorylation of serine, threonine, and tyrosine (+79.9663@
[STY]). The search results were then post-processed using PeptideProphet and ProteinProphet [45] [46] [47] . Spectral counts were obtained for each cell line using ABACUS 48 . Immunoprecipitation data of phospho-tyrosine enrichment were processed through ABACUS separately from the MOAC enrichment data. ABACUS results were filtered to only retain proteins with a ProteinProphet probability >0.7. Only phosphorylated peptides with a probability >0.8 were considered for spectral counting. For tyrosine enrichment these ABACUS parameters resulted in a protein false discovery rate (FDR) of 0.0045. This ABACUS output was used for all subsequent analysis to quantify the relative abundance of phosphorylated peptides or proteins. Phospho-site localization was performed with an in-house reimplementation of the Ascore algorithm as previously described 49 . Ascore values represent the probability of detection owing to chance, with scores >19 corresponding to sites localized with >99% certainty. From four biological replicates, the application of stringent criteria selected 22 top-scoring candidate substrates of F3-T3 that exhibited at least a 1.5-fold enrichment in F3-T3 human astrocytes compared to human astrocytes expressing F3-T3(K508M) or the empty vector (Supplementary Table 2 ). Identification of PIN4 complexes by mass spectrometry. Endogenous cellular PIN4 complexes were purified from the cell line H1299 transduced with the F3-T3-expressing lentivirus. Cellular lysates were prepared in 50 mM Tris-HCl, 250 mM NaCl, 0.2% NP40, 1 mM EDTA, 10% glycerol, protease and phosphatase inhibitors. PIN4 and mock immunoprecipitates were recovered with PIN4 antibody (Abcam, ab155283) and rabbit IgG, respectively. Immunocomplexes captured on protein A/G agarose beads were washed with lysis buffer containing 300 mM NaCl and 0.3% NP40. Bound polypeptides were eluted with the PIN4 peptide used as the epitope for the PIN4 antibody (KPVFTDPPVKTKFGYH, Abcam, ab155283). Eluates were run on SDS-PAGE gels and four gel slices were cut from the lane containing PIN4 immunoprecipitates (columns A1, B1, C1, D1; Supplementary Table 8 ). Four similar gel slices were cut from the lane containing control rabbit IgG immunoprecipitates (columns A2, B2, C2, D2; Supplementary Table 8 ). The excised gel pieces were rehydrated and digested in 80 μl of 12.5 ng μl −1 Trypsin Gold and 50 mM ammonium bicarbonate at 37 °C overnight. Extracted peptides were dried, reconstituted in 30 μl 0.1% TFA and stored at −20 °C before analysis.
The concentrated peptide mix was reconstituted in a solution of 2% acetonitrile (ACN), 2% formic acid (FA) and eluted from the column using a Dionex Ultimate 3000 Nano LC system. The application of a 2.0-kV distal voltage electrosprayed the eluting peptides directly into the Thermo Fusion Tribrid mass spectrometer equipped with an EASY-Spray source (Thermo Scientific). Mass spectrometerscanning functions and HPLC gradients were controlled by the Xcalibur data system (Thermo Finnigan). Tandem mass spectra from raw files were searched against a human protein database using the Proteome Discoverer 1.4 software (Thermo Finnigan). The peptide mass search tolerance was set to 10 p.p.m. A minimum sequence length of seven amino acids residues was required. Only fully tryptic peptides were considered. Spectral counts were used for estimation of relative protein abundance between samples analysed directly on long gradient reverse phase liquid chromatography-tandem mass spectrometry. A specificity score of proteins interacting with PIN4 was computed for each polypeptide as described 50 . In brief, we compared the number of peptides identified from our mass spectrometry analysis to those reported in the CRAPome database that includes a list of potential contaminants from affinity purification-mass spectrometry experiments (http://www.crapome.org/). The specificity score is computed as (p × c) / S av × S max × E, where p is the identified peptide count; c the cross-correlation score for all candidate peptides queried from the database; S av the averaged spectral counts from CRAPome; S max the maximal spectral counts from CRAPome; and E the total number of experiments that were found in the CRAPome database. Cell culture. Human cell lines. h-TERT-immortalized human astrocytes 51 , SF126 cells 52 , U87 (ATCC HTB-14), h-TERT-RPE-1 (ATCC CRL-4000), HEK293T (ATCC CRL-11268), U251 (Sigma 09063001) cells. Cell lines were cultured in DMEM supplemented with 10% fetal bovine serum (FBS, Sigma). Cells were transfected using Lipofectamine 2000 (Invitrogen) or the calcium phosphate method. Mouse glioma stem cells. F3-T3;shTrp53 and HRAS(12V);shTrp53 mGSCs were isolated from the brains of mice that had received injection of lentivirus containing a bi-cistronic expression cassette including F3-T3 or HRAS(12V) and Trp53 shRNA into the dentate gyrus as described 4, 7 . Mice showing neurological symptoms were euthanized 2-4 months after intracranial injection, and brain tumours were identified macroscopically, dissected and cultured in DMEM:F12 containing 1× N2 and B27 supplements (Invitrogen) and human recombinant FGF2 and EGF (20 ng ml −1 each; Peprotech). Studies were approved by the IACUC at Columbia University (AAAL7600). Human glioma stem cells. The GBM-derived glioma stem cells (GSCs) used in this study have been described previously 4, 12 . GBM-derived GSCs were grown in DMEM:F12 containing 1× N2 and B27 supplements (Invitrogen) and human recombinant FGF2 and EGF (20 ng ml −1 each; Peprotech). Cells were transduced using lentiviral particles in medium containing 4 μg ml −1 of polybrene (Sigma). Cells were routinely tested for mycoplasma contamination using the Mycoplasma Plus PCR Primer Set (Agilent Technologies) and were found to be negative. Cell authentication was performed using short-tandem repeats (STR) at the ATCC facility.
Limiting dilution assay (LDA) for human GSCs was performed as described previously 50 . In brief, spheres were dissociated into single cells and plated into 96-well plates in 0.2 ml of medium containing growth factors at increasing densities (1-100 cells per well) in triplicate. Cultures were left undisturbed for 14 days, and then the percentage of wells not containing spheres for each cell dilution was calculated and plotted against the number of cells per well. Linear regression lines were plotted, and we estimated the minimal frequency of glioma cells endowed with stem cell capacity (the number of cells required to generate at least one sphere in every well = the stem cell frequency) based on the Poisson distribution and the intersection at the 37% level using Prism 6.0 software. Data represent the means of three independent experiments performed on different days.
The soft agar colony assay was performed by seeding human astrocytes at a density of 10,000 cells per well in 6-well plates in 0.3% agar in DMEM and 10% FBS. The number of colonies per well was determined using an Olympus 1X70 microscope equipped with a digital camera. Subcutaneous xenograft glioma models. Mice were housed in a pathogen-free animal facility. All animal studies were approved by the IACUC at Columbia University (AAAQ2459; AAAL7600). Mice were 4-6 week old male and female athymic nude (Nu/Nu, Charles River Laboratories). No statistical method was used to pre-determine sample size. No method of randomization was used to allocate animals to experimental groups. Mice in the same cage were generally part of the same treatment. The investigators were not blinded during outcome assessment. In none of the experiments did tumours exceed the maximum volume allowed according to our IACUC protocol, specifically, 20 mm in the maximum diameter. 5 × 10 5 F3-T3 human astrocytes transduced with a lentivirus expressing the shRNA sequence against PPARGC1A or ESRRG or the empty vector were injected subcutaneously in the right flank in 150 μl of saline solution (five mice per group). 0.5 × 10 5 F3-T3;shTrp53 mGSCs and HRAS(12V);shTrp53 mGSCs transduced with lentivirus expressing two independent shRNA sequences against PPARGC1A were injected subcutaneously in the right flank in 100 μl of saline solution (five mice per group). Treatment with tigecycline (10 mice) or vehicle (8 mice) was performed in mice injected with 1 × 10 5 F3-T3;shTrp53 mGSCs when tumours reached 150-270 mm 3 (10 days after injection). Tigecycline was diluted in saline pH 7 and administered at dose of 50 mg kg −1 body weight by intraperitoneal injection b.i.d. Tumour diameters were measured daily with a caliper and tumour volumes estimated using the formula: (width 2 × length) / 2 = V (mm 3 ). Mice were euthanized when tumour size reached the maximum diameter allowed by our IACUC protocol (20 mm in the maximum diameter) or when mice displayed body weight loss equal to or greater than 20% of total body mass, or showed signs of compromised health or distress. Plasmids, cloning, and lentivirus production. cDNAs for FGFR3, PIN4, PKM2, GOLGIN84, DLG3, C1ORF50 and PPARGC1A were amplified by PCR and cloned into the pLOC vector in frame with Flag or V5 tag. F3-T3, F3-T3 K508M and FLAG-tagged PEX1 were cloned into a pLVX-puro vector (Clontech). To generate PIN4(Y122A), PIN4(Y122F), PKM2(Y105A), GOLGIN84(Y42A), DLG3(Y673A) and C1orf50(Y131A), site-directed mutagenesis was performed using the QuickChange Site-Directed mutagenesis kit (Agilent) and the resulting plasmids were sequence verified. Lentivirus was produced by co-transfection of the lentiviral vectors with pCMV-ΔR8.1 and pCMV-MD2.G plasmids into HEK293T cells as previously described 7, 16 . shRNA sequences are: PIN4 shRNA: GTCAGACACATTCTATGTGAACTCGAGTTCACATAGAATGTGTCTGAC; PPARGC1A Hs-shRNA1: GCAGAGTATGACGATGGTATTCTCGAGAA TACCATCGTCATACTCTGC; PPARGC1A Hs-shRNA2: CCGT T ATACCTGTGATGCTTTCTCGAGAAAGCATCACAGGTATAACGG; Ppargc1a Mm-shRNA1: C CA GAACAAGAACAACGGTTTCTCGAGAAACCGT TGTTCTTGTTCTGG; Ppargc1a Mm-shRNA2: CCCATTTGAGAACAAGAC TATCTCGAGATAGTCTTGTTCTCAAATGGG; ESRRG shRNA1: CAAACAA AGATCGACACATTGCTCGAGCAATGTGTCGATCTTTGTTTG; ESRRG shRNA2: CATGAAGCGCTGCAGGATTATCTCGAGATAATCCTGC AGCGCTTCATG.
For the generation of PPARGC1A-knockout F3-T3 human astrocytes with CRISPR-Cas9, guide RNA (gRNA) sequences were designed to target the coding sequence of PPARGC1A as described (http://crispr.mit.edu/). We designed two gRNAs against exon 1 of the PPARGC1A gene and validated three clones for loss of PGC1α expression. sgRNA sequence 1 (GGCGTGGGACATGTGCAACC) and 2 (ACCAGGACTCTGAGTCTGTA) were inserted by linker cloning in the lentiviral vector pLCiG2 53, 54 . Human astrocytes expressing the empty vector or F3-T3 were infected either with pLCiG2 and control, pLCiG2 and PPARGC1A gRNA1 or pLCiG2 and PPARGC1A gRNA2. After 72 h of infection, cells were seeded in a 96-well plate at a density of 0.6 cell per well. Two weeks later, colonies were isolated and PPARGC1A deletion was analysed by RT-qPCR and western blot. For acute expression of F3-T3 in human astrocytes, cells were first transduced with pLOC expressing Flag-PIN4(WT) or the Y122F mutant. Subsequently, cells were transduced with a pLKO.1-puro vector encoding shRNA targeting PIN4. The levels of endogenous and ectopically expressed proteins were then verified by immunoblotting. Finally, cells were transduced with a pLVX vector expressing F3-T3. Generation of phospho-PIN4(Y122) antibody. The anti-phospho-PIN4 antibody was generated by immunizing rabbits with a short synthetic peptide Letter reSeArCH containing phosphorylated Y122 (underlined) (PVKTKFGYHIIMVE) (Yenzym Antibodies, LLC). A two-step purification process was applied. First, antiserum was cross-absorbed against the phospho-peptide matrix to purify antibodies that recognized the phosphorylated peptide. Next, the anti-serum was purified against the un-phosphorylated peptide matrix to remove non-specific antibodies. Antibodies were validated using lysates from cells transfected with PIN4(WT) or the phospho-mutant PIN4(Y122A). Immunoblot and immunoprecipitation. For western blot, cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP40, 0.5% sodium dexoycholate, 0.1% sodium dodecyl sulphate, 1.5 mM Na 3 VO 4 , 10 mM sodium fluoride, 10 mM sodium pyrophosphate, 10 mM β-glycerolphosphate and EDTA-free protease inhibitor cocktail, Roche). Lysates were cleared by centrifugation at 15,000 r.p.m. for 15 min at 4 °C. Phospho-tyrosine immunoprecipitation was performed on cells that were freshly collected in cold PBS containing Na 3 VO 4 and lysed in RIPA buffer. Subsequently, 800 μg of protein extract was incubated with 30 μl of phospho-tyrosine sepharose beads (P-Tyr-100, Cell Signaling Technology, 9419) in a final volume of 800 μl overnight at 4 °C. Beads were washed five times with cold RIPA buffer and eluted by 2× SDS sample buffer. Immunoprecipitates were separated by SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were blocked in TBS with 5% non-fat milk and 0.1% Tween-20, and probed with primary antibodies overnight at 4 °C. PIN4 and Flag-PEX1 immunoprecipitation was performed on cells that were freshly collected in cold PBS and lysed in 50 mM Tris pH 8.0, 150 mM NACl, 0.5% NP40, 1 mM EDTA, 10% glycerol, protease and phosphatase inhibitors. Subsequently, 2,000 μg of protein extract was incubated with PIN4 antibody (Abcam, ab155283) at a concentration of 0.6 μg mg −1 cell lysate or Flag-M2 agarose beads in a final volume of 1,000 μl overnight at 4 °C. For PIN4 immunoprecipitation, Protein A/G Plus agarose beads (Santa Cruz Biotechnology) were added for 2 h at 4 °C. Beads were washed five times with cold lysis buffer including 300 mM NaCl, and immunocomplexes were eluted with PIN4 or Flag-M2 peptide at room temperature for 4 h or 45 min, respectively. Immunoprecipitates were separated by SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were blocked in TBS with 5% non-fat milk and 0.1% Tween-20, and probed with primary antibodies overnight at 4 °C.
Antibodies and concentrations were: FGFR3 1:1,000 (Santa Cruz, B-9, sc-13121), PIN4 1:1,000 (Abcam, ab155283), PKM2 1:1,000 (Cell Signaling, 3198), DLG3 (also known as SAP102) 1:1,000 (Cell Signaling, 3733), GOLGIN84 1:2,000 (Santa Cruz, H-283, sc-134704), C1orf50 1:1,000 (Novus Biologicals, NBP1-81053), HGS 1:1,000 (Abcam, ab72053), FAK 1:1,000 (Cell Signaling, 3285), Paxillin 1:1,000 (BD Transduction, 610051), PGC1α 1:500 (Santa Cruz, H300, sc-13067), PGC1α 1:1,000 (Novus Biological, NBP104676), ERRγ 1:500 (Abcam, ab128930), ERRγ 1:500 (R7D, PP-H6812000), phospho-FRS2 1:1,000 (Cell Signaling, 3861), FRS2 1:1,000 (Santa Cruz, sc-8318), phospho-STAT3 1:1,000 (Cell Signaling, 9131), STAT3 1:1,000 (Santa Cruz, C-20, sc-482,), phospho-AKT 1:1,000 (Cell Signaling, 4060), AKT 1:1,000 (Cell Signaling, 9272), phospho-ERK1/2 1:1,000 (Cell Signaling, 4370), ERK1/2 1:1,000 (Cell Signaling, 9102), β-actin 1:2,000 (Sigma, A5441), PEX1 1:500 (BD Biosciences, 611719), PEX6 1:500 (Stress Marq, SMC-470), NUP214 1:500 (Abcam, ab70497), SEC16A 1:500 (Abcam, ab70722), DHX30 1:500 (Novus Biologicals, NBP1-26203), SUN-2 1:500 (Abcam, ab124916), Flag 1:1,000 (Abcam, ab1162), retinoblastoma 1:1,000 (BD Pharmingen, 554136), α-tubulin 1:2,000 (Sigma, T5168), total OXPHOS 1:1,000 (Abcam, ab110411), MTCO1 1:1,000 (Abcam, ab14705). Secondary horseradish-peroxidase-conjugated antibodies were purchased from Pierce and Enhanced ChemiLuminescence (Amersham) or Super Signal West Femto (Thermo Scientific) was used for detection. RT-qPCR. Total RNA was prepared using the Trizol reagent (Invitrogen) and cDNA was synthesized using SuperScript II Reverse Transcriptase (Invitrogen) as described 16, 55 . RT-qPCR was performed with a Roche 480 thermal cycler, using SYBR Green PCR Master Mix (Applied Biosystems). RT-qPCR results were analysed by the ΔΔC t method 56 using 18S or Actb as the housekeeping gene. Human primers used for RT-qPCR were as follows. UQCRC1 forward 5′-CACC GTGATGATGCTCTACC-3′ and reverse 5′-CCACCACCATAAGTGCAGTC-3′; POLRMT forward 5′-TATTCATGGTGAAGGATGCC-3′ and reverse 5′-TCTGT TCCAGACACCTTTCG-3′; NDUFB4 forward 5′-TGCTTCAGTACAACGA TCCC-3′ and reverse 5′-CACACAGAGCTCCCATGAGT-3′; MRPL15 forward 5′-TGCTTCCACCAGAAGAACTG-3′ and reverse 5′-ACTTCCTGGCGA GTTCAAGT-3′; MCL1 forward 5′-GCATCGAACCATTAGCAGAA-3′ and reverse 5′-TGCCACCTTCTAGGTCCTCT-3′; MRPS30 forward 5′-TATTC CTCGTGGTCATCGAA-3′ and reverse 5′-CTCTGCGAGTTGCTTGGATA-3′; TIMM10 forward 5′-CCTGGACCGATGTGTCTCTA-3′ and reverse 5′-GCACCCT CTTCATCAGCTCT-3′; NRF1 forward 5′-GGAAACGGCCTCATGTATTT-3′ and reverse 5′-TCATCTAACGTGGCTCGAAG-3′; ATP5G3 forward 5′-CCCAGAATG GTGTGTCTCAG-3′ and reverse 5′-TTCCAATACCAGCACCAGAA-3′; ABCE1 forward 5′-TCATTGATCAAGAGGTGCAGA-3′ and reverse 5′-TAGACATC AGCAGGTTTGCC-3′; TIMM23 forward 5′-GGATTGAAGGAAACCCAGAA-3′ and reverse 5′-CCCTTGCCTAGTCACCATATT-3′; TFAM forward 5′-GCTC AGAACCCAGATGCAA-3′ and reverse 5′-CACTCCGCCCTATAAGCATC-3′; TIMM9 forward 5′-TGAAGAGACCACCTGTTCAGA-3′ and reverse 5′-AAGGAGTCCTGCTTTGGCT-3′; TIMM44 forward 5′-TCCAA GACAGAGATGTCGGA-3′ and reverse 5′-GATGTCGTTCTCGCACTGTT-3′; VDAC1 forward 5′-AATGTGAATGACGGGACAGA-3′ and reverse 5′-ACAGCGG TCTCCAACTTCTT-3′; NDUFA9 forward 5′-TATGCATCGGTTTGGTCCTA-3′ and reverse 5′-GACCAACGAAAGCAAAGGAT-3′; NDUFV2 forward 5′-AAAG GCAGAATGGGTGGTT-3′ and reverse 5′-CTTTCCAACTGGCTTTCGAT-3′; COX5A forward 5′-GATGCTCGCTGGGTAACATA-3′ and reverse 5′-GGGCTCTG GAACCATATCAT-3′; NDUFS5 forward 5′-TGGTGAACAGCCCTACAAGA-3′ and reverse 5′-TCTGCCCGAGTATAACCGAT-3′; NDUFA2 forward 5′-CGTCAG GGACTTCATTGAGA-3′ and reverse 5′-AAGGGACATTCGTCTCTTGG-3′; PITRM1 forward 5′-TCTCGGATGAGATGAAGCAG-3′ and reverse 5′-CCCAG TGCCGAGGTATCTAT-3′; CISD1 forward 5′-TGACTTCCAGTTCCAGCGTA-3′ and reverse 5′-GATAACCAATTGCAGCTGTCC-3′; ATP5G1 forward 5′-AGCTCT GATCCGCTGTTGTA-3′ and reverse 5′-GGAAGTTGCTGTAGGAAGGC-3′; MRPL12 forward 5′-TCAACGAGCTCCTGAAGAAA-3′ and reverse 5′-GTGTC CGTTCTTTCGCTATG-3′; IDH3A forward 5′-CCGACCATGTGTCTCTATCG-3′ and reverse 5′-GCACGACTCCATCAACAATC-3′; 18S forward 5′-CGCCG CTAGAGGTGAAATTC-3′ and reverse 5′-CTTTCGCTCTGGTCCGTCTT-3′; PPARGC1A forward 5′-CTCACACCAAACCCACAGAG-3′ and reverse 5′-GTGT TGTGACTGCGACTGTG-3′; PEX1 forward 5′-AGTCACCAGCCTGCA TTCTT-3′ and reverse 5′-ATGGGAACATGGCTTGAGAA-3′. Mouse primers used in RT-qPCR were as follows. Ppargc1a forward 5′-GACAG CTTTCTGGGTGGATT-3′ and reverse 5′-CGCAGGCTCATTGTTGTACT-3′; Actb forward 5′-GATGACGATATCGCTGCGCTG-3′ and reverse 5′-GTACGACCAGAGGCATACAGG-3′. Quantification of mitochondrial DNA content. Total DNA was isolated using the Puregene Blood Core kit (Qiagen) according to the manufacturer's instructions. Mitochondrial DNA content was measured using real-time quantitative PCR (qPCR) as previously described 57 . In brief, relative quantification of mitochondrial DNA content for each sample was determined using a set of mitochondrial specific primers: mt-Mito: forward 5′-CACTTTCCACACAGACATCA-3′, reverse 5′-TGGTTAGGCTGGTGTTAGGG-3′; and a set of nuclear-specific primers: B2M forward 5′-TGTTCCTGCTGGGTAGCTCT-3′ and reverse 5′-CCTCCATGATG CTGCTTACA-3′. qPCR was performed with a Roche 480 thermal cycler, using SYBR Green PCR Master Mix (Applied Biosystems). qPCR conditions used were: 95 °C for 10 min followed by 40 cycles at 95 °C for 15 s, 72 °C for 15 s followed by a melting cycle going up to 95 °C. Primer specificity was determined by melt curve analysis and agarose gel electrophoresis, confirming a single band of the amplification product. The relative mitochondrial DNA content was calculated using the
. Mitochondria analysis by flow cytometry. Cells were seeded in 60-mm dishes and cultured in DMEM containing 10% FBS. Cells were washed once with FBSfree medium. Mitotracker Red (LifeTechnologies, M7212) was added to a final concentration of 20-40 nM and incubated for 20-30 min at 37 °C. Cells were then quickly washed with PBS, trypsinized, collected in phenol-red-free medium and incubated for 10 min at 37 °C in the dark before analysis. Unstained cells were used as a negative control. Acquisition was performed on LSR II Flow Cytometer (BD Biosciences) on the basis of forward and sideward scatter parameters and Texas red fluorescence using BD FACSDiva software. Eight to ten thousand events from each sample were evaluated. Data were analysed using the FCS Express 6 Flow software (De novo Software). Metabolic assays. Measurement of oxygen consumption rate and extracellular acidification rate. The functional status of mitochondria in cells expressing F3-T3 was determined by analysing multiple parameters of oxidative metabolism using the XF96 Extracellular Flux Analyzer (Agilent), which measures the extracellular flux changes of oxygen and protons. Cells were plated in XF96-well microplates (6,000-7,000 cells per well) in a final volume of 80 μl of DMEM medium (25 mM glucose, 2 mM glutamine) supplemented with 10% FBS, 48 h before the assay. For experiments requiring AZD4547 treatment, cells were plated as previously described in the presence of 150 nM of AZD4547. For the mitochondrial stress test, cells were washed twice with 200 μl of XF Assay Medium Modified DMEM (Agilent), supplemented with 25 mM glucose, 2 mM glutamine (XF-Mito-MEM) and incubated at 37 °C in the absence of CO 2 for 1 h before the assay in 180 μl per well of XF-Mito-MEM. The ports of the sensor cartridge were sequentially loaded with 20 μl per well of the appropriate compound: the ATP coupler oligomycin (Sigma, O4876), the uncoupling agent carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, Sigma C2920) and the complex I inhibitor rotenone (Sigma, R8875). Compound concentration used for the different cell lines are indicated in Supplementary Table 9a . For the glycolysis stress test, cells were washed twice with (XF-Glyco-MEM) and incubated at 37 °C in the absence of CO 2 for 1 h before the assay in 180 μl per well of XF-Mito-MEM. The ports of the sensor cartridge were sequentially loaded with 20 μl per well of the appropriate compound: glucose (10 mM final concentration; Sigma, 8769), oligomycin (2 μM final concentration; Sigma, O4876) and 2-DG (100 mM final concentration; Sigma, 8375). OCR and ECAR were measured through 16 rates: 4 rates under basal conditions, 4 rates after oligomycin or glucose injection, 4 rates after FCCP or oligomycin injection, and 4 rates after rotenone or 2-DG injection, for OCR or ECAR evaluation, respectively. The protocol was: mix (2 min), wait (1 min) and measure (2 min). OCR and ECAR values were normalized to the number of cells per well. The ratio OCR:ECAR was determined by dividing the normalized value of rate 4 of the OCR (basal condition) with the normalized value of rate 8 of the ECAR (after glucose injection). ATP assay. Cells were cultured in DMEM medium containing 25 mM glucose, 2 mM glutamine and 10% FBS. After 24 h, 5,000 cells per 130 μl were plated in opaque white 96-well plates in 5 mM glucose, 2 mM glutamine and 0.2% FBS DMEM medium. CellTiterGlo assay reagent (Promega, G7570) was added 12-16 h later, according to the manufacturer's instructions and luminescence was measured using a GloMax-Multi+ Microplate Multimode Reader (Promega). For experiments testing the effect of oligomycin, cells were cultured in glucose-free DMEM medium for 24 h and ATP levels were determined as described above. Cell growth assay. Time-course analysis of cellular growth of human astrocytes expressing F3-T3 or the empty vector was performed by plating 12,500 cells per well in triplicate in 6-well plate in DMEM containing 10% FBS. After 24 h, cells were washed and cultured in glucose-free DMEM medium containing 0.2% FBS and supplemented with 25 mM glucose or 25 mM galactose in the presence or absence of 100 nM oligomycin. Viable cells were scored every two days by Trypan blue exclusion. Survival assays of human and mouse GSCs treated with mitochondrial inhibitors were performed by plating 25,000 cells per well in 12-well plates in triplicate. Cells were counted after 72 h. Gene set enrichment analysis (GSEA) for ROS detoxification genes. We generated a gene set of 46 genes participating in ROS detoxification programs by combining genes extracted from specific references 20, 58 and the detoxification of reactive oxygen species reactome pathway R-HSA-3299685 (http://reactome. org/pages/download-data/). The full list of genes is reported in Supplementary  Table 7c . The GSEA analysis was performed comparing the gene expression of F3-T3-expressing and vector control-transduced human astrocytes using default settings 59 . Analysis of protein biosynthesis and ROS by high content microscopy. Human astrocytes transduced as indicated in the figure legends were plated at a density of 6,000 cells per well in 96-well clear-bottom black plates (Greiner) 18 h before the analysis in preparation for the evaluation of both protein biosynthesis and cellular ROS. Protein biosynthesis was detected by the Click-iT Plus OPP Alexa Fluor-594 protein synthesis assay kit (Molecular Probes, C10457). Cells were incubated in the dark with O-propargyl-puromycin (OPP) reagent at a concentration of 10 μM for 30 min. Identical samples were treated with CHX at a concentration of 30 μM for 30 min before addition of OPP reagent and used as negative controls. Samples were washed with Click-iT rinse buffer, fixed in 3.7% formaldehyde for 15 min followed by permeabilization in 0.5% Triton X-100 for 15 min. Click-iT OPP reaction cocktail was then added for 30 min followed by one wash in Click-iT rinse buffer and nuclear counterstaining with DAPI. Acquisition of fluorescence intensity was performed using an IN Cell Analyzer 2000 (GE Healthcare) equipped with a 2,048 × 2,048 CCD camera. Assay conditions were: two-colour assay (DAPI and Cy3), 20× objective, exposure time 0.5 ms for Cy3 and 0.1 ms for DAPI. Four fields around the centre of each well, including 2,000 to 6,000 cells, were imaged. Data were analysed using IN Cell Investigator software (GE Healthcare). Fluorescence intensity was normalized to the number of cells as determined by the number of DAPI-positive objects in each well.
For determination of cellular ROS, cells were incubated in the dark with CellROX Deep Red reagent at concentration of 2.5 μM for 30 min at 37 °C. Identical samples were treated with N-acetyl-l-cysteine at concentration of 5 μM for 2 h before addition of CellROX Deep Red reagent and used as negative controls. Samples were washed once with PBS, fixed in 3.7% formaldehyde for 15 min followed by two additional washes in PBS and nuclear counterstaining with DAPI. Acquisition of fluorescence intensity was performed as described above. Assay conditions were: two-colour assay (DAPI and Cy5), 20× objective, exposure time 0.8 ms for Cy5 and 0.1 ms for DAPI. Four fields around the centre of each well, including 2,000 to 6,000 cells, were imaged. Data were analysed using IN Cell Investigator software (GE Healthcare). Fluorescence intensity was normalized to the number of cells as determined by the number of DAPI-positive objects in each well. Immunofluorescence of cultured cells and primary tissue. Cells were fixed with 4% paraformaldehyde containing 4% sucrose, permeabilized with 0.1-1% Triton X-100, 0.1% BSA in TBS for 4 min at 4 °C, and blocked with 3% BSA, 0.05% Triton X-100 in TBS. The primary antibodies used were as follows: phospho-PIN4 (1:100); PMP70 (Sigma, SAB4200181, 1:150); PEX1 (BD Bioscience, 611719, 1:100); FGFR3 (Santa Cruz, sc-13121 B9, 1:1,000). Secondary antibodies were anti-mouse Alexa Fluor-647, anti-rabbit Alexa Fluor-568, or Cy3-conjugated (Molecular Probes, Invitrogen). Nuclei were stained with DAPI (Sigma).
Fluorescence microscopy was performed on a Nikon A1R MP microscope using a 100×, 1.45 Plan Apo Lambda lens. Images were recorded with a z-optical spacing of 0.15 μm and analysed using the NIS Elements Advanced Research software (Nikon Instruments). The number of peroxisomes per cell was scored as the average of PMP70 + in five z sections (one at the equatorial plane and two above and two below the equatorial plane). Quantification of PEX1 fluorescence intensity was performed on maximum intensity images of z sections. After calibration and thresholding, the integrated density (product of the area and the mean intensity value (IMFI)) was averaged between 30 cells in at least six representative pictures per sample.
Tissue preparation and immunostaining on mouse and human tissues were performed as previously described 7, 50, 60 . The human GBM samples analysed by immunostaining had been stored in the Onconeurotek Tumourbank (certified NF S96 900), and received the authorization for analysis from ethical comittee (CPP Ile de France VI, A39II), and French Ministry for research (AC 2013 (AC -1962 . In brief, tumour sections were deparaffinized in xylene and rehydrated in a graded series of ethyl alcohol. Antigen retrieval was performed in citrate solution pH 6.0 using a decloaking chamber (10 min for phosho-PIN4 and 7 min for COXIV, VDAC, NDUFS4 and FGFR3). Primary antibodies were incubated at 4 °C overnight: COXIV (Cell Signaling, 4850, 1:1,500), VDAC1 (Abcam, ab14734, 1:700), NDUFS4 (Abcam, ab55540, 1:700), phosho-PIN4(Y122) (1:200) and FGFR3 (Santa Cruz, B9, sc-13121, 1:500). Sections were incubated in biotinylated secondary antibody for 1 h, followed by 30 min of streptavidin-HRP-conjugated (Vector Laboratories) for phosho-PIN4(Y122), FGFR3, VDAC1, and NDUFS4 or HRP-conjugated antirabbit secondary antibody (DAKO) for COXIV and TSA-Cy3 or TSA-Fluorescein (Perkin-Elmer). Nuclei were counterstained with DAPI (Sigma). Images were acquired using 20× magnification using an Olympus 1X70 microscope equipped with digital camera. Quantification of fluorescence intensity was performed using NIH ImageJ software. After calibrating and standardizing the 8-bit grayscale images, the integrated density (IMFI) was averaged between three 20× representative pictures per sample section. Drosophila studies. The UAS-F3-T3 flies were generated by inserting the human F3-T3 fusion gene into the pACU2 plasmid followed by embryo injection of the plasmid and selection of the correct transgenic fly. All other genotypes were established through standard genetics. repo-Gal4 was used to drive gene expression in the glial lineage. UAS-eGFP or UAS-mRFP were introduced to visualize and quantify tumour volume. repo-Gal4;UAS-dEGFR λ ;UAS-Dp110 CAAX (as previously described 24 ) and repo-Gal4;UAS-F3-T3 stocks were balanced over the CyoWeeP and TM6B balancers. srl RNAi lines were obtained from the Bloomington Drosophila Stock Center (BDSC) and the Vienna Drosophila Resource Center (VDRC): P{KK100201}VIE-260B (VDRC v103355), y 1 sc* v 1 ; P{TRiP.GL01019} attP40 (BDSC 57043), y 1 sc* v 1 ; P{TRiP.HMS00857}attP2 (BDSC 33914), and y 1 sc* v 1 ; P{TRiP.HMS00858}attP2 (BDSC 33915). The following ERR RNAi lines were used: y 1 v 1 ; P{TRiP.JF02431}attP2 (BDSC 27085), y 1 v 1 ; P{TRiP.HMC03087} attP2 (BDSC 50686) and P{KK108422}VIE-260B (VDRC v108349). y 1 v 1 ; P{UAS-GFP.VALIUM10}attP2 (BDSC 35786) was used as a control for RNAi experiments. Fly culture, immunohistochemistry and imaging. Flies were mated and maintained at 29 °C. Fly larvae were retrieved at late third instar stage for brain dissections followed by fixation and immunohistochemical analysis. Larval brains were dissected, fixed and stained as previously described 61 . In brief, third instar larval brains were dissected in PBS, fixed in 4% paraformaldehyde solution for 20 min at room temperature, and incubated with primary antibodies, including: rat anti-phospho-histone H3 (Abcam, ab10543, 1:300) and mouse anti-Repo (Developmental Study Hybridoma Bank, 1:60) overnight at 4 °C and secondary antibody for 2 h at room temperature. Fluorescence images were acquired using a Leica SP8 confocal microscope. Image analysis. To determine tumour volume, we acquired image stacks using a Leica SP8 confocal microscope with a z-step size of 5.0 μm per optical slice using a 20× objective throughout the entire thickness of the brain and ventral nerve cord. The confocal LIF files were converted into Imaris files using ImarisFileConverter 6.4.2. All subsequent image processing was conducted with Imaris 5.5 software. z-series stacks were used to make three-dimensional reconstructions. A smooth level of 1.0 was used on every measurement for consistency. Brain tumour volumes were quantified using three-dimensional reconstructions. Statistical analysis. In general, two to four independent experiments were performed. Comparisons between groups were analysed by t-test with Welch correction (two-tailed, unequal variance) and/or the MWW non-parametric test when
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Extended Data Figure 1 | Activation of mitosis and mitochondria by F3-T3. a, Immunoblot analysis of FGFR3 and phospho-FGFR3 in F3-T3 human astrocytes treated with DMSO or PD173074, or human astrocytes expressing F3-T3(K508M) or vector. β-Actin is shown as a loading control. Experiment was repeated at least five times with similar results. b, Heat map of correlations among F3-T3 human astrocytes, F3-T3 human astrocytes treated with PD173074, and human astrocytes expressing vector or F3-T3(K508M). Top and right track colours represent sample type; left track colour scale represents correlation between each sample and the F3-T3 group. F3-T3 human astrocytes and F3-T3 human astrocytes treated with PD173074 (n = 5 biologically independent samples per group). Human astrocytes expressing vector or F3-T3(K508M) (n = 3 biologically independent samples per group). c, Enrichment map network of GO categories scoring as significant (Q < 10 −6 in each comparison) from three independent GSEAs (F3-T3 human astrocytes versus F3-T3 human astrocytes treated with PD173074; F3-T3-versus F3-T3(K508M)expressing human astrocytes; F3-T3-versus vector-expressing human astrocytes). Nodes represent GO terms and lines indicate their connectivity. Size of nodes is proportional to enrichment significance and thickness of lines indicates the fraction of genes shared between the groups. d, RT-qPCR of vector-or F3-T3-expressing human astrocytes treated with vehicle (DMSO) or PD173074 for 12 h. Data are fold change relative to vector (dotted line) of one representative experiment out of two independent experiments (data are mean ± s.d., n = 3 technical replicates). P values were calculated using a two-tailed t-test with unequal variance; *P < 0.05, **P < 0.01, ***P < 0.001. For a complete list of P values see Source Data. e, Left, analysis of mitochondrial mass by MitoTracker FACS analysis in human astrocytes expressing F3-T3, F3-T3(K508M) or vector. Right, quantification of mean fluorescence intensity (MFI). Data are mean ± s.d. of three (vector and F3-T3) and two (F3-T3(K508M)) independent experiments. *P < 0.05, **P < 0.01; two-tailed t-test with unequal variance. f, Immunoblot analysis of mitochondrial proteins in human astrocytes expressing F3-T3, F3-T3(K508M) and vector. Experiment was repeated independently three times with similar results. g, Representative micrographs of VDAC1 and NDUFS4 immunofluorescence (top, green) in F3-T3;shTrp53 and HRAS(12V);shTrp53 mGSCs. DAPI staining of nuclei is shown as an indication of cellular density (bottom, blue). Experiment was repeated independently twice with similar results. Molecular weights are indicated on all immunoblots.
Extended Data Figure 2 | F3-T3 induces sensitivity to inhibitors of mitochondrial metabolism. a, Immunoblot analysis using the FGFR3 antibody in human astrocytes expressing vector, F3-T3 or F3-T3(K508M). α-Tubulin is shown as a loading control. Experiment was repeated five times with similar results. b, OCR of GSC1123 cells expressing F3-T3 in the presence or absence of AZD4547. Data are mean ± s.d. (n = 6 technical replicates) of one representative experiment out of two independent experiments. P < 0.001 for rate 1-4 and 9-12, two-tailed t-test with unequal variance. c, OCR of RPE cells expressing F3-T3, F3-T3(K508M) or the empty vector in the presence or absence of AZD4547. Data are mean ± s.d. (n = 3 technical replicates) of one representative experiment out of three independent experiments performed in triplicate with similar results. P < 0.05 for rate 1-4; P < 0.001 for rate 9-12; two-tailed t-test with unequal variance. d, OCR of U251 cells expressing F3-T3, F3-T3(K508M) or the empty vector in the presence or absence of AZD4547. Data are mean ± s.d. (n = 3 technical replicates) of one representative experiment out of two independent experiments performed in triplicate with similar results. P < 0.01 for rate 1-4; P < 0.001 for rate 9-12; two-tailed t-test with unequal variance. e, ECAR of human astrocytes expressing F3-T3, F3-T3(K508M) or the empty vector. Data are mean ± s.d. (n = 3 technical replicates) of one representative experiment out of two independent experiments performed in triplicate with similar results. P < 0.01 for rate 9-12; two-tailed t-test with unequal variance. f, Ratio between OCR (rate 4) and ECAR (rate 8) in human astrocytes expressing F3-T3, F3-T3(K508M) or vector. Data are mean ± s.d. (n = 6 replicates) of two independent experiments each performed in triplicate. P < 0.01; twotailed t-test with unequal variance. g, Quantification of ATP production in human astrocytes expressing F3-T3 or vector following treatment with the indicated concentrations of oligomycin for 72 h. Data are independent technical replicates (n = 4) and means (connecting lines) of one representative experiment out of two independent experiments performed with similar results. **P < 0.01; ***P < 0.001; two tailed t-test with unequal variance. h, Time-course analysis of cellular growth of human astrocytes expressing F3-T3 or vector cultured in the presence of glucose (25 mM) or galactose (25 mM) with or without oligomycin (100 nM). Data are independent technical replicates (n = 3) of one representative experiment out of two independent experiments performed with similar results. ***P < 0.001; two-tailed t-test with unequal variance. i-k, Survival ratio of F3-T3;shTrp53 and HRAS(12V);shTrp53 mGSCs treated for 72 h with vehicle or metformin (i), rotenone (j) or menadione (k) at the indicated concentrations. Data are mean ± s.d. (n = 3 technical replicates) of one representative experiment out of two independent experiments performed with similar results. **P < 0.01; ***P < 0.001; two-tailed t-test with unequal variance. l, Western blot analysis of COX1 and COX2 proteins in F3-T3;shTrp53 and HRAS(12V);shTrp53 mGSCs treated with vehicle or tigecycline at a concentration of 8 μM for 72 h. α-Tubulin is shown as a loading control. Experiment was independently repeated twice with similar results. m, Quantification of cellular ATP in F3-T3;shTrp53 (left) and HRAS(12V);shTrp53 (right) mGSCs treated with vehicle or metformin (1 mM), tigecycline (8 μM) or menadione (5 μM) for 16 h. Data are mean ± s.d. of one experiment (n = 6 technical replicates). **P < 0.01; ***P < 0.001; two-tailed t-test with unequal variance. n, Quantification of tumour volume of F3-T3;shTrp53 mGSCs in control and tigecyclinetreated mice. Data are tumour volumes (median with interquartile range) at day 6 of treatment, a time when all mice were still in the study; n = 8 for control (median = 1,427 mm 3 ) and n = 10 for tigecycline-treated mice (median = 843.4 mm 3 ). *P < 0.05; two-sided Mann-Whitney U-test. Molecular weights are indicated in immunoblots.
Extended Data Figure 10 | Acute expression of F3-T3 fusion induces peroxisome biogenesis through phosphorylation of PIN4(Y122). a, Representative confocal images (maximum intensity) of immunofluorescence staining for total PIN4 (PIN4, red, left) and phospho-PIN4(Y122) (p-PIN4, red, middle panel) in human astrocytes expressing the empty vector and F3-T3. Right, higher magnification of dotted boxes. Nuclei were counterstained with DAPI (blue). Experiment was repeated independently twice with similar results. b, Maximum intensity of confocal images of double immunofluorescence staining for FGFR3 (green, middle) and phospho-PIN4(Y122) (red, right) in human astrocytes expressing F3-T3. Arrows indicate protein co-localization. Experiment was repeated independently twice with similar results. c, Co-immunoprecipitation from H1299 cells using the PIN4 antibody. Endogenous PIN4 immunocomplexes and input (WCL) were analysed by western blot using the indicated antibodies. Input is 10% for PEX1, PEX6, SUN2 and NUP214; 5% for SEC16A and DHX30; 2% for PIN4. d, Western blot analysis of co-immunoprecipitation of exogenous Flag-PEX1 in human astrocytes expressing F3-T3. WCL: 1% for PIN4 and 10% for PEX1 and PEX6. Experiment was repeated independently four times with similar results. e, RT-qPCR of PEX1 in human astrocytes expressing F3-T3 or vector. Data are mean ± s.d. (n = 3 technical replicates) of one representative experiment out of three independent experiments performed in triplicate. f, Western blot analysis of PEX1 expression in human astrocytes transduced with F3-T3, F3-T3(K508M) or the empty vector. β-Actin is shown as a loading control. Experiment was repeated independently three times with similar results. g, Time-course analysis of F3-T3 expression in human astrocytes by western blot. α-Tubulin is shown as a loading control. Experiment was repeated independently twice with similar results. h, Quantification of protein biosynthesis by OPP incorporation measured by high-content fluorescent microscopy in human astrocytes reconstituted with PIN4(WT) or PIN4(Y122F) after silencing of the endogenous PIN4 and acutely transduced with F3-T3 or vector. Representative bar plots (n = 4 technical replicates) from one out of three independent experiments. *P < 0.05, ***P < 0.001; twotailed t-test with unequal variance. CHX-treated cultures were used as negative controls. i, Time-course expression analysis by RT-qPCR of the indicated mitochondrial genes in human astrocytes expressing F3-T3 or empty vector. Data are mean ± s.d. (n = 3 technical replicates) of one representative experiment out of two independent experiments performed in triplicate. Values were normalized to vector (dotted line). *P < 0.05, **P < 0.01, ***P < 0.001; two-tailed t-test with unequal variance. j, Quantification of cellular ROS (measured by high-content microscopy) in human astrocytes reconstituted with PIN4(WT) or PIN4(Y122F) after silencing of the endogenous PIN4 and acutely transduced with F3-T3 or vector. Representative bar plots from one out of three independent experiments. Data are mean ± s.d. (n = 3 technical replicates). *P < 0.05; two-tailed t-test with unequal variance. N-acetyl-l-cysteine-treated cultures were used as negative controls. Molecular weights are indicated in all immunoblots. Corresponding author(s): Antonio Iavarone
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Experimental design 1. Sample size
Describe how sample size was determined.
No statistical methods were used to predetermine sample size. Samples sizes were selected based on previous experience to obtain statistical significance and reproducibility.
Data exclusions
Describe any data exclusions. No data were excluded from the analyses
Replication
Describe whether the experimental findings were reliably reproduced.
Experimental findings were reliably reproduced in multiple independent experiments as indicated throughout the manuscript.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No randomization method was applied. Male and female mice were included in treated and control groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators were not blinded during data collection and analysis.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
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